Skip to main content
SpringerLink
Log in

Drug approval in Europe

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Abstract

The EMEA gets good grades, but has room for improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: The EMEA's centralized procedure for approval of medicinal products within the EU.

References

  1. Office for Official Publications of the European Communities, 2 Rue de Mercier, L-2985, Luxembourg.

Download references

Acknowledgements

The author wishes to acknowledge the EMEA home page and annual reports as the source of much of the data provided. The assistance of various EMEA staff is also acknowledged, as is that of the regulatory affairs personnel of various companies who responded to an informal survey carried out in preparation for this article.

Author information

Authors and Affiliations

  1. lecturer in industrial biochemistry at the University of Limerick, Limerick, Ireland

    Gary Walsh

Authors
  1. Gary Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walsh, G. Drug approval in Europe. Nat Biotechnol 17, 237–240 (1999). https://doi.org/10.1038/6977

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/6977

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation